ASA Anti-sperm Ab IgG ELISA test |
|||
| 118 | Biobase | 96T/Box | Ask for price |
|
Description: ELISA based test for quantitative detection of ASA Anti-sperm Ab IgG |
|||
Human IgG antibody Laboratories manufactures the interpositive on sars cov2 ab test reagents distributed by Genprice. The Interpositive On Sars Cov2 Ab Test reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Interpositive products are available in stock. Specificity: Interpositive Category: On Group: Sars Cov2
CMV (Cytomegalovirus Antibody IgG) ELISA test |
||
| Biobase | 96T/Box | Ask for price |
|
Description: ELISA based test for quantitative detection of CMV (Cytomegalovirus Antibody IgG) |
||
ACA (Anticardiolipin Antibody IgG) ELISA test |
||
| Biobase | 96T/Box | Ask for price |
|
Description: ELISA based test for quantitative detection of ACA (Anticardiolipin Antibody IgG) |
||
TOX (Toxoplasma Antibody IgG) ELISA test |
||
| Biobase | 96T/Box | Ask for price |
|
Description: ELISA based test for quantitative detection of TOX (Toxoplasma Antibody IgG) |
||
ANA (Antinuclear Antibody IgG) ELISA test |
||
| Biobase | 96T/Box | Ask for price |
|
Description: ELISA based test for quantitative detection of ANA (Antinuclear Antibody IgG) |
||
HCV Ab hepatitis C antibody ELISA test |
||
| Biobase | 96T/Box | Ask for price |
|
Description: ELISA based test for quantitative detection of HCV Ab hepatitis C antibody |
||
HAV-Ab hepatitis A antibody ELISA test |
||
| Biobase | 96T/Box | Ask for price |
|
Description: ELISA based test for quantitative detection of HAV-Ab hepatitis A antibody |
||
HEV-Ab hepatitis E antibody ELISA test |
||
| Biobase | 96T/Box | Ask for price |
|
Description: ELISA based test for quantitative detection of HEV-Ab hepatitis E antibody |
||
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
| 9159P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
| 9161P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
| 9163P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
| 9167P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
| 9171P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
| 9173P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP4 Peptide |
|||
| 9175P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP6 Peptide |
|||
| 9177P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) NSP6 Peptide |
|||
SARS-CoV-2 (COVID-19) ORF6 Peptide |
|||
| 9189P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) ORF6 Peptide |
|||
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
| 9287P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
| 9289P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
| 9155-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
|||
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
| 9155-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
|||
SARS-CoV-2 (COVID-19) NSP8 Antibody |
|||
| 9159-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
|||
SARS-CoV-2 (COVID-19) NSP8 Antibody |
|||
| 9159-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
|||
SARS-CoV-2 (COVID-19) NSP9 Antibody |
|||
| 9161-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
|||
SARS-CoV-2 (COVID-19) NSP9 Antibody |
|||
| 9161-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
|||